Brokerage recommends buying recently listed midcap stock; sees 22.14% upside

Are you searching for newly listed stocks to invest in long-term perspective? Analysts from domestic brokerage have initiated coverage on Dr Agarwal's Health Care stock with a potential upside of 22.14 per cent and cited that the latent demand for eye care is expected to drive industry outperformance over the next five years.

"DAHL has delivered a revenue and EBITDA CAGR of 38 per cent, 41 per cent, respectively over FY22-24 aided by organic as well as inorganic growth levers...DAHL is strengthening its reach by deepening market penetration and expanding through a hub and spoke model, currently operating 28 hubs and 193 spokes," the brokerage said. 

MOFSL recommends buying DAHL shares; check out targets

Analysts at the brokerage have suggested buying the healthcare sector for a target of Rs 510. The given targets implies a potential upside of 22.14 per cent from Wednesday's (March 19) closing.

Dr Agarwal's Healthcare Stock: Past Performance

The stock has gained around 8 per cent from the listing price (Rs 402), same as the upper price band of the IPO, apiece on the NSE website.

Dr Agarwal's Healthcare Stock Listing Details

On Tuesday, February 4, 2025, Dr Agarwal's Health Care stock opened at Rs 402 on the NSE, which was the same as its IPO price. While on another exchange BSE, it was listed at Rs 396.90, which is 1.27 per cent lower than the issue price.

The company's IPO worth Rs 3,027.26 crore window was available for subscription from January 29 to January 31. The price range for the IPO was set between Rs 382 and Rs 402 per share.